newsPhase III trial results indicate BeiGene’s tislelizumab improved overall survival…
16 August 2022 | By Caroline Peachey (European Pharmaceutical Review)
Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.